Trade Policy

A new report this weekend revealed how the wife of Senator Ron Wyden (D-Ore.) has maintained significant financial ties to Big Tech companies even as the Senate Finance Committee Chairman is playing a leading role in Big Tech’s global push for deregulation.

Yet despite these promises, email correspondence obtained through FOIA requests by Demand Progress show that senior officials across USTR, including Deputy U.S. Trade Representative Sarah Bianchi, actively seek input from executives at Big Tech firms such as Amazon and Google. Giving Big Tech a privileged ability to mold American trade policy undermines Biden’s commitment to a new era of trade deals.

One tiny federal agency with 116 full-time employees and a $28.9 million dollar budget is in charge of regulating the global marine economy, which contributes $397 billion to the US GDP annually and accounts for 80 percent of goods shipped worldwide. That’s not just an apples and oranges discrepancy—that’s like an apple versus Apple. The budget for the military’s marching bands is fifteen times greater than the Federal Maritime Commission’s budget; the Marines alone have five times more musicians than the Commission has staff.

When United States Trade Representative Katherine Tai announced this past May that the U.S. would support the TRIPS waiver on COVID-19 vaccines at the World Trade Organization (WTO), we at the Revolving Door Project celebrated the administration’s decision as “a transformative, hopeful event.” The waiver proposal calls on the WTO’s Trade-Related Aspects of Intellectual Property Rights (TRIPS) Council to suspend intellectual-property protections on COVID-19 therapeutics, diagnostics, and vaccines to ensure materials necessary for combating the pandemic are “available promptly, in sufficient quantities and at affordable price to meet global demand.”

The Commerce Secretary is a dedicated corporate crony. Making her Treasury Secretary would be a catastrophic mistake.

In 2019, Gallup found that the pharmaceutical industry was “the most poorly regarded industry in Americans’ eyes,” and rightfully so. Pharmaceutical companies often set drug prices exorbitantly high, including life-saving drugs which patients literally cannot go without, such as insulin. This includes older drugs that are cheaper to produce — such as epinephrine (emergency medication used to treat severe allergic reactions and asthma attacks). These firms achieve this by stifling competition at the consumer’s expense, jealously protecting their money-makers from the generics which the pharmaceutical system is supposed to develop after a patent expires.

The Biden administration is divided over whether to waive trade protections for Big Pharma—with Commerce Secretary Gina Raimondo as a key industry ally.

With his nomination of Katherine Tai, who has advocated for a worker-centered trade policy, Biden demonstrated his commitment to transforming the trade agenda in the Democratic party. Unfortunately, his choice of Sarah Bianchi to serve as deputy USTR could undermine these efforts: